. 2022 Mar 23;11(5):e210456. doi: 10.1530/EC-21-0456
This work is licensed under a Table 2.
Serum and urinary bone and mineral metabolism-related parameters, stratified by MEN1-associated tumors.
| Parameterd | Total patients (n = 101) | Patients with PHPT (n = 76) | Patients without PHPT (n = 25) | Patients with GEP-NET (n = 34) | Patients without GEP-NET (n = 67) | Patients with functioning pituitary adenoma (n = 33) | Patients without functioning pituitary adenoma (n = 68) | Patients without the three main MEN1 tumors (n = 20) | Patients with only PHPT (n = 30) | Patients with only GEP-NET (n = 1) | Patients with only functioning pituitary adenoma (n = 3) | Patients with PHPT and GEP-NET (n =18) | Patients with PHPT and functioning pituitary adenoma (n = 14) | Patients with GEP-NET and functioning pituitary adenoma (n = 1) | Patients with PHPT, GEP-NET and functioning pituitary adenoma (n = 14) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at tumor diagnosis (years) | n.a. | 33.0 ± 13.8 | n.a. | 37.0 ± 13.7 | n.a. | 27.5 ± 11.3 | n.a. | n.a. | 31.3 ± 14.9 | 38 | 32.0 ± 12.5 | PHPT: 40.2 ± 12.8;GEP-NET: 39.9 ± 14.2 |
PHPT: 28.4 ± 10.2;Functioning pituitary adenoma: 24.1 ± 9.2 |
GEP-NET: 41; Functioning pituitary adenoma: 15 |
PHPT: 31.6 ± 13.0;GEP-NET: 32.8 ± 13.4;Functioning pituitary adenoma: 31.1 ± 12.6 |
| Age at biochemical measurement (years) | 35.3 ± 16.2 | 38.3 ± 15.7 | 26.2 ± 14.5 | 40.9 ± 14.8 | 32.5 ± 16.2 | 36.0 ± 12.3 | 35.0 ± 17.8 | 22.6 ± 12.7 | 36.6 ± 17.7 | 42 | 40.3 ± 17.5 | 45.2 ± 15.6 | 36.0 ± 11.3 | 42 | 35.4 ± 13.5 |
| Gap between tumor development and biochemical measurement (years) | n.a. | 5.3 ± 7.8 | n.a. | 3.9 ± 5.6 | n.a. | 7.8 ± 6.5 | n.a. | n.a. | 5.3 ± 10.3 | 4 | 8.0 ± 4.6 | PHPT: 4.9 ± 6.6;GEP-NET: 5.3 ± 7.1 |
PHPT: 6.2 ± 6.3;Functioning pituitary adenoma: 11.9 ± 6.7 |
GEP-NET: 1; Functioning pituitary adenoma: 27 |
PHPT: 3.8 ± 3.7;GEP-NET: 2.4 ± 2.8;Functioning pituitary adenoma: 4.3 ± 4.8 |
| Parathyroid hormone (1.3–7.6 pmol/L) | 14.4a ± 14.1 | 16.4a ± 15.5 | 6.8 ± 3.1 | 17.0a ± 15.3 | 12.5a ± 13.3 | 18.5a ± 20.4 | 11.8a ± 9.1 | 5.9 ± 1.7 | 14.6a ± 11.1 | 7.8a | 8.0a ± 3.4 | 13.6a ± 6.0 | 18.4a ± 22.0 | 10.1a | 21.7a ± 22.4 |
| Serum calcium ion (4.3–5.3 mg/dL) | 5.5a ± 0.5 | 5.5a ± 0.5 | 5.6a ± 0.5 | 5.6a ± 0.6 | 5.4a ± 0.5 | 5.6a ± 0.5 | 5.4a ± 0.5 | 5.0 ± 0.4 | 5.7a ± 0.3 | 4.5 | 5.0 ± 0.3 | 5.5a ± 0.6 | 5.6a ± 0.5 | 5.6a | 5.7a ± 0.5 |
| Total serum calcium (8.5–10.1 mg/dL) | 10.1 ± 0.9 | 10.4a ± 0.9 | 9.2 ± 0.6 | 10.3a ± 0.9 | 10.0 ± 0.9 | 10.2a ± 0.9 | 10.1 ± 1.0 | 9.3 ± 0.6 | 10.5a ± 0.8 | 8.2 | 9.4 ± 0.5 | 10.4a ± 0.9 | 10.2a ± 0.9 | 9.4 | 10.4a ± 0.9 |
| Serum phosphate (2.5–4.9 mg/dL) | 2.7 ± 0.8 | 2.5 ± 0.6 | 3.4 ± 1.0 | 2.6 ± 0.8 | 2.8 ± 0.8 | 2.4b ± 0.5 | 2.9 ± 0.9 | 3.5 ± 0.9 | 2.4b ± 0.7 | 5.6a | 2.6 ± 0.6 | 2.6 ± 0.5 | 2.5 ± 0.4 | 2.6 | 2.2a ± 0.5 |
| 25-hydroxy-vitamin D (30–100 ng/mL) | 22.8b ± 11.1 | 21.8b ± 11.3 | 25.6b ± 10.2 | 20.2b ± 12.9 | 24.1b ± 9.9 | 21.5b ± 10.5 | 23.5b ± 11.4 | 27.0b ± 8.5 | 22.2b ± 8.9 | 4.8b | 26.1b ± 17.1 | 22.1b ± 16.2 | 22.7b ± 12.0 | 20.3b | 19.0b ± 7.7 |
| Bone alkaline phosphatase (Men: 7–20 µg/L; pre-menopausal women: 4–14.3 µg/L; post-menopausal women: 6–22.5 µg/L)c | 26.9b ± 20.8 | 24.1b ± 14.1 | 33.6b ± 31.3 | 22.8b ± 10.2 | 28.9b ± 24.2 | 26.8b ± 18.5 | 27.0b ± 22.1 | 38.8b ± 33.7 | 20.8b ± 9.7 | 10.2 | 16.0 ± 2.9 | 21.7b ± 5.2 | 30.5a ± 23.0 | 17.1 | 26.2a ± 14.6 |
| Urinary calcium (42–353 mg/24 h) | 274.8 ± 163.1 | 325.2 ± 156.5 | 139.6 ± 86.5 | 305.8 ± 138.9 | 260.1 ± 172.7 | 335.2 ± 155.3 | 244.6 ± 159.8 | 136.2 ± 159.8 | 308.4 ± 173.7 | 66.0 | 120.9 ± 74.7 | 288.7 ± 143.6 | 372.5a ± 164.9 | 327.0 | 351.7 ± 120.7 |
| Urinary phosphate (400–1300 mg/24 h) | 747.2 ± 272.3 | 777.9 ± 284.9 | 665.1 ± 221.2 | 770.8 ± 290.5 | 737.1 ± 266.4 | 762.1 ± 260.4 | 739.5 ± 280.4 | 692.0 ± 247.3 | 775.7 ± 299.4 | 569.0 | 565.9 ± 69.2 | 750.9 ± 307.1 | 766.8 ± 256.2 | 628.0 | 835.6 ± 299.1 |
| Urinary deoxypyridinoline (3.0–5.4 mnol/mmol creatinine) | 8.0a ± 4.5 | 7.5a ± 3.7 | 9.4a ± 6.0 | 6.7a ± 3.1 | 8.6a ± 4.9 | 7.9a ± 3.6 | 8.1a ± 4.9 | 10.4a ± 6.5 | 8.1a ± 4.0 | 4.5 | 5.8a ± 1.4 | 5.2a ± 2.0 | 7.9a ± 4.1 | 9.4a | 8.5a ± 3.5 |
aA parameter value higher than the normal range; bA parameter value less than the normal range; cReference values for bone alkaline phosphatase from our hospital analysis laboratory are referred to adult men and adult women; dReferral normal values for bone and mineral metabolism biochemical parameters are indicated within brackets.
GEP-NETs, gastro-entero-pancreatic neuroendocrine tumors; n.a., not applicable; PHPT, primary hyperparathyroidism.